Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.54 |
| ▸ | CCR2 | P41597 | 1/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5487610 | 0.94 | OPRD1 (0.61) | OPRD1OPRM1OPRK1LTA4H | |
| SCHEMBL6399567 | 0.94 | KDM4E (0.59) | OPRD1OPRM1OPRK1ROCK2CCR2 | |
| SCHEMBL6156841 | 0.84 | GAA (0.59) | DRD2DRD4ROCK2CCR2ROCK1 | |
| SCHEMBL6394117 | 0.83 | OPRD1 (0.58) | OPRD1OPRM1OPRK1 | |
| SCHEMBL6393640 | 0.82 | KDM4E (0.56) | OPRD1OPRM1OPRK1ROCK2CCR2 | |
| SCHEMBL5630413 | 0.81 | LTA4H (0.60) | DRD2DRD4LTA4H | |
| SCHEMBL331018 | 0.80 | BCHE (0.68) | OPRK1DRD2DRD4ROCK2CCR2 | |
| SCHEMBL331017 | 0.80 | BCHE (0.68) | OPRK1DRD2DRD4ROCK2CCR2 | |
| SCHEMBL6870724 | 0.79 | OPRD1 (0.77) | OPRD1OPRM1OPRK1 | |
| SCHEMBL14492922 | 0.78 | POLB (0.52) | OPRD1OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6974825-B1 | Compounds with analgesic effect | ASTRAZENECA CANADA INC. (CA) | 2005-12-13 | — | — | US | disclosed |
| EP-1428821-A1 | Piperidin-4-yl amines with analgesic effect | AstraZeneca AB (SE) | 2004-06-16 | — | — | EP | disclosed |
| EP-0946510-B1 | NOVEL COMPOUNDS WITH ANALGESIC EFFECT | ASTRAZENECA AB (SE) | 2004-05-12 | — | — | EP | disclosed |
| US-6710179-B2 | FOR THERAPY OF PAIN | ASTRAZENECA CANADA INC. (CA) | 2004-03-23 | — | — | US | disclosed |
| US-20030055045-A1 | Novel compounds with analgesic effect | ASTRA PHARMA INC. | 2003-03-20 | — | — | US | disclosed |
| US-6399635-B1 | N,N-DIETHYL-4-(N-PIPERIDIN-3-YL-ANILINO) BENZAMIDE COMPOUND; REDUCTIVE AMINATION OF A 3-PIPERIDONE, ARYLATION | ASTRAZENECA CANADA INC. (CA) | 2002-06-04 | — | — | US | disclosed |
| US-6153626-A | Compounds with analgesic effect | ASTRA PHARMA INC. (CA) | 2000-11-28 | — | — | US | disclosed |
| EP-0946510-A1 | NOVEL COMPOUNDS WITH ANALGESIC EFFECT | Astra Pharma Inc. (CA) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028270-A1 | NOVEL COMPOUNDS WITH ANALGESIC EFFECT | ASTRA PHARMA INC. (CA) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055045-A1 | Novel compounds with analgesic effect | OPRM1, OPRL1, OPRK1 | OPRD1 4/4885OPRM1 1/4885OPRK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.